RU2015125332A - Способы профилактики метастазирования опухолей, лечения и прогнозирования рака и идентификации агентов, которые являются предполагаемыми ингибиторами метастазирования - Google Patents
Способы профилактики метастазирования опухолей, лечения и прогнозирования рака и идентификации агентов, которые являются предполагаемыми ингибиторами метастазирования Download PDFInfo
- Publication number
- RU2015125332A RU2015125332A RU2015125332A RU2015125332A RU2015125332A RU 2015125332 A RU2015125332 A RU 2015125332A RU 2015125332 A RU2015125332 A RU 2015125332A RU 2015125332 A RU2015125332 A RU 2015125332A RU 2015125332 A RU2015125332 A RU 2015125332A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- inhibitor
- synj2
- metastasis
- onset
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 24
- 238000000034 method Methods 0.000 title claims 24
- 201000011510 cancer Diseases 0.000 title claims 16
- 206010027476 Metastases Diseases 0.000 title claims 6
- 230000009401 metastasis Effects 0.000 title claims 6
- 239000003795 chemical substances by application Substances 0.000 title claims 4
- 239000002257 antimetastatic agent Substances 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 claims 12
- 102000000580 synaptojanin Human genes 0.000 claims 10
- 108010016910 synaptojanin Proteins 0.000 claims 10
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 6
- 102000006240 membrane receptors Human genes 0.000 claims 6
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 238000012875 competitive assay Methods 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 238000010561 standard procedure Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000002875 fluorescence polarization Methods 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
Claims (22)
1. Способ профилактики метастазирования опухолей при том условии, что опухоль не является глиомой, причем способ включает введение нуждающемуся в этом пациенту терапевтически эффективного количества ингибитора синаптоянина 2 (SYNJ2), который предотвращает метастазирование опухолей.
2. Ингибитор синаптоянина 2 (SYNJ2) для профилактики метастазирования опухолей при том условии, что опухоль не является глиомой.
3. Способ лечения рака, причем способ включает введение нуждающемуся в этом пациенту терапевтически эффективного количества ингибитора синаптоянина 2 (SYNJ2) и ингибитора рецептора клеточной поверхности, связанного с началом или прогрессированием рака, этим осуществляя лечение рака.
4. Ингибитор синаптоянина 2 (SYNJ2) и ингибитор рецептора клеточной поверхности, связанного с началом или прогрессированием рака для лечения рака.
5. Способ по п. 3, отличающийся тем, что упомянутым рецептором клеточной поверхности, связанным с упомянутым наступлением или прогрессированием рака, является рецепторная тирозинкиназа.
6. Способ по п. 5, отличающийся тем, что упомянутой рецепторной тирозинкиназой является рецепторный белок ErbB.
7. Способ по п. 6, отличающийся тем, что упомянутым рецепторным белком ErbB является рецептор эпидермального фактора роста (РЭФР).
8. Способ идентификации предполагаемого ингибитора метастазирования опухолей, причем способ включает анализ SYNJ2-опосредованного процессинга PI(3,4,5)P3 в PI(3,4)P2 в присутствии контрольного агента, отличающийся тем, что пониженный процессинг PI(3,4,5)P3 в PI(3,4)P2 в присутствии упомянутого контрольного агента по сравнению с процессингом в его отсутствие указывает на предполагаемый ингибитор метастазирования опухолей.
9. Способ по п. 8, отличающийся тем, что упомянутый анализ SYNJ2-опосредованного процессинга PI(3,4,5)P3 в PI(3,4)P2 выполняют путем конкурентного анализа.
10. Способ по п. 9, отличающийся тем, что упомянутый конкурентный анализ анализирует смещение PI(3,4)P2-связывающего домена из комплекса, включающего упомянутый PI(3,4)P2-связывающий домен, связанный с PI(3,4)P2.
11. Способ по любому одному из пп. 9 и 10, отличающийся тем, что упомянутым конкурентным анализом является конкурентный анализ с флуоресцентной поляризацией.
12. Способ прогнозирования рака у нуждающегося в этом пациента, причем способ включает определение уровня или активности SYNJ2 в раковой клетке пациента, отличающийся тем, что возрастание упомянутого уровня активности SYNJ2 в упомянутой раковой клетке пациента по сравнению с таковым в клетке незатронутой контрольной пробы указывает на плохой прогноз.
13. Способ по п. 12, кроме того включающий подтверждение упомянутого прогноза использованием метода золотого стандарта.
14. Способ по п. 13, отличающийся тем, что упомянутый метод золотого стандарта включает детекцию маркера.
15. Способ по п. 14, отличающийся тем, что упомянутый маркер выбирают из группы, состоящей из HER-2 и эстрогенного рецептора (ER).
16. Способ по п. 1, отличающийся тем, что упомянутое метастазирование является ЭФР-зависимым.
17. Способ по п. 3 или 12, отличающийся тем, что упомянутым раком является рак груди.
18. Способ по п. 1 или 3, отличающийся тем, что упомянутый ингибитор SYNJ2 выбирают из группы, состоящей из малой молекулы, антитела, пептида и агента сайленсинга нуклеиновой кислоты.
19. Способ по п. 18, отличающийся тем, что упомянутую малую молекулу выбирают из молекул, указанных в Таблице 2.
20. Изделие для лечения рака или профилактики метастазирования рака, включающее упаковочный материал, в который упакован ингибитор SYNJ2 и ингибитор рецептора клеточной поверхности, связанного с началом или прогрессированием рака.
21. Способ по п. 3 или изделие по п. 20, отличающиеся тем, что упомянутым ингибитором упомянутого рецептора клеточной поверхности, связанного с наступлением или прогрессированием рака, является антитело.
22. Способ по п. 3 или изделие по п. 20, отличающиеся тем, что упомянутым ингибитором упомянутого рецептора клеточной поверхности, связанного с наступлением или прогрессированием рака, является ингибитор малой молекулы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731003P | 2012-11-29 | 2012-11-29 | |
| US61/731,003 | 2012-11-29 | ||
| PCT/IL2013/050986 WO2014083567A2 (en) | 2012-11-29 | 2013-11-28 | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015125332A true RU2015125332A (ru) | 2017-01-10 |
Family
ID=49880888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015125332A RU2015125332A (ru) | 2012-11-29 | 2013-11-28 | Способы профилактики метастазирования опухолей, лечения и прогнозирования рака и идентификации агентов, которые являются предполагаемыми ингибиторами метастазирования |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150290233A1 (ru) |
| EP (1) | EP2925359A2 (ru) |
| JP (1) | JP2016502536A (ru) |
| KR (1) | KR20150090116A (ru) |
| CN (1) | CN104822390A (ru) |
| AU (1) | AU2013350721A1 (ru) |
| BR (1) | BR112015002626A2 (ru) |
| CA (1) | CA2877847A1 (ru) |
| HK (1) | HK1213189A1 (ru) |
| IL (1) | IL238015A0 (ru) |
| IN (1) | IN2014MN02655A (ru) |
| MX (1) | MX2015004626A (ru) |
| RU (1) | RU2015125332A (ru) |
| WO (1) | WO2014083567A2 (ru) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
| LT3372605T (lt) | 2008-10-22 | 2022-02-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP3521291A1 (en) | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
| EP3074044A2 (en) | 2013-11-28 | 2016-10-05 | Yeda Research and Development Co., Ltd. | Synaptojanin-2 inhibitors and uses thereof |
| EP3218380B1 (en) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| EP3281151B1 (en) * | 2015-04-10 | 2023-03-29 | President and Fellows of Harvard College | Methods and devices for live cell imaging analysis |
| RS61485B1 (sr) | 2015-07-16 | 2021-03-31 | Array Biopharma Inc | Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze |
| US20180209956A1 (en) * | 2015-07-17 | 2018-07-26 | University Of Iowa Research Foundation | HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies |
| KR20180102544A (ko) | 2015-10-26 | 2018-09-17 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
| EP3800189B1 (en) | 2016-05-18 | 2023-06-28 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| TWI680295B (zh) * | 2017-03-02 | 2019-12-21 | 即時量測細胞聚落之裝置及其方法 | |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CN107898799A (zh) * | 2017-11-20 | 2018-04-13 | 中国科学院昆明植物研究所 | Paeonivayin在制备治疗中枢神经系统疾病的药物中的应用 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物 |
| CN112533643A (zh) * | 2018-03-28 | 2021-03-19 | 得克萨斯州大学系统董事会 | 外排体用于靶向递送治疗剂的用途 |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP3643183A1 (en) * | 2018-10-26 | 2020-04-29 | Analyticon Discovery GmbH | Preparations with c-methyl flavonoids |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| WO2020252346A1 (en) * | 2019-06-14 | 2020-12-17 | POWELL, Brooks | Formulations of dihydromyricetin and a permeabilizer |
| KR20220123023A (ko) | 2019-12-27 | 2022-09-05 | 슈뢰딩거, 인크. | 시클릭 화합물 및 이의 사용 방법 |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| JP2024505890A (ja) | 2021-01-26 | 2024-02-08 | シュレーディンガー， インコーポレイテッド | がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113730587A (zh) * | 2021-09-23 | 2021-12-03 | 澳门大学 | Fgfr及其相关信号通路抑制剂在制备治疗fgfr2突变型肿瘤的药物中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| US6348185B1 (en) | 1998-06-20 | 2002-02-19 | Washington University School Of Medicine | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6410061B1 (en) * | 1999-03-30 | 2002-06-25 | Purdue Research Foundation | Tea catechins as cancer specific proliferation inhibitors |
| WO2003057239A1 (en) * | 2001-12-28 | 2003-07-17 | Research Development Foundation | Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| JP4922551B2 (ja) * | 2004-06-22 | 2012-04-25 | エル．ビー．メープル トリート コーポレーション | 生理活性フェノール性化合物を強化してなるメープルシロップ |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER |
| WO2008156644A2 (en) * | 2007-06-14 | 2008-12-24 | Frank David A | Stat modulators |
| EP2119434A1 (en) * | 2008-05-13 | 2009-11-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of heterosidic flavonoid derivatives for therapy of stem cell cancers |
-
2013
- 2013-11-28 BR BR112015002626A patent/BR112015002626A2/pt not_active Application Discontinuation
- 2013-11-28 CA CA2877847A patent/CA2877847A1/en not_active Abandoned
- 2013-11-28 US US14/432,520 patent/US20150290233A1/en not_active Abandoned
- 2013-11-28 RU RU2015125332A patent/RU2015125332A/ru not_active Application Discontinuation
- 2013-11-28 MX MX2015004626A patent/MX2015004626A/es unknown
- 2013-11-28 IN IN2655MUN2014 patent/IN2014MN02655A/en unknown
- 2013-11-28 EP EP13812170.2A patent/EP2925359A2/en not_active Withdrawn
- 2013-11-28 CN CN201380062068.6A patent/CN104822390A/zh active Pending
- 2013-11-28 KR KR1020157015567A patent/KR20150090116A/ko not_active Application Discontinuation
- 2013-11-28 WO PCT/IL2013/050986 patent/WO2014083567A2/en active Application Filing
- 2013-11-28 JP JP2015544614A patent/JP2016502536A/ja active Pending
- 2013-11-28 AU AU2013350721A patent/AU2013350721A1/en not_active Abandoned
-
2015
- 2015-03-29 IL IL238015A patent/IL238015A0/en unknown
-
2016
- 2016-02-02 HK HK16101210.4A patent/HK1213189A1/zh unknown
-
2017
- 2017-02-22 US US15/438,806 patent/US20170165285A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014MN02655A (ru) | 2015-08-21 |
| US20150290233A1 (en) | 2015-10-15 |
| CA2877847A1 (en) | 2014-06-05 |
| KR20150090116A (ko) | 2015-08-05 |
| CN104822390A (zh) | 2015-08-05 |
| BR112015002626A2 (pt) | 2017-09-26 |
| WO2014083567A8 (en) | 2014-08-21 |
| WO2014083567A3 (en) | 2014-07-24 |
| US20170165285A1 (en) | 2017-06-15 |
| AU2013350721A1 (en) | 2015-01-29 |
| JP2016502536A (ja) | 2016-01-28 |
| IL238015A0 (en) | 2015-05-31 |
| EP2925359A2 (en) | 2015-10-07 |
| WO2014083567A2 (en) | 2014-06-05 |
| HK1213189A1 (zh) | 2016-06-30 |
| MX2015004626A (es) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015125332A (ru) | Способы профилактики метастазирования опухолей, лечения и прогнозирования рака и идентификации агентов, которые являются предполагаемыми ингибиторами метастазирования | |
| Price et al. | Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism | |
| Viana et al. | Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination | |
| Lee et al. | Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer | |
| Lee et al. | The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer | |
| Dai et al. | TWEAK promotes ovarian cancer cell metastasis via NF-κB pathway activation and VEGF expression | |
| ATE493442T1 (de) | Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie | |
| RU2014110228A (ru) | Диагностические маркеры | |
| Lin et al. | Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition | |
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| Wang et al. | Astrocyte elevated gene-1 (AEG-1) promotes osteosarcoma cell invasion through the JNK/c-Jun/MMP-2 pathway | |
| Dai et al. | Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library | |
| Oshima et al. | Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines | |
| Ren et al. | Protein overexpression of CIRP and TLR4 in oral squamous cell carcinoma: an immunohistochemical and clinical correlation analysis | |
| WO2011109625A4 (en) | Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification | |
| Asp et al. | Flotillin depletion affects ErbB protein levels in different human breast cancer cells | |
| EP2304051B1 (en) | Human mena isoform serve as marker for sensitivity to egfr inhibition in human cancer cells | |
| Ben Jemaa et al. | A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP | |
| Lorenzatti Hiles et al. | ADAM15 is functionally associated with the metastatic progression of human bladder cancer | |
| Heldin et al. | Dynamin inhibitors impair platelet-derived growth factor β-receptor dimerization and signaling | |
| Sun et al. | Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma | |
| He et al. | Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| Ieguchi et al. | Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer | |
| Lu et al. | Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161129 |